This article is for educational purposes. If you suspect insulin resistance, consult your GP for testing and personalised management.
Insulin resistance and weight loss are deeply connected — and understanding that connection is one of the most important things you can do for your metabolic health. For millions of Australians carrying excess weight, particularly around the abdomen, insulin resistance is not a downstream consequence of their weight problem but a central driver of it. Reversing insulin resistance is not only possible in the majority of cases — it is one of the most impactful metabolic interventions available, and the evidence base for how to do it is robust.
This guide covers what insulin resistance is, how to test for it in Australia, and the diet, exercise, supplement, and medication strategies that have the strongest evidence for reversing it.
Insulin is a hormone produced by the beta cells of the pancreas. Its primary job is to act as a key — unlocking cells so that glucose from the bloodstream can enter and be used for energy or stored. When you eat carbohydrates, blood glucose rises, the pancreas releases insulin, and cells throughout the body — particularly muscle, liver, and fat tissue — take up that glucose.
In insulin resistance, cells stop responding normally to insulin's signal. The key no longer fits the lock as efficiently. The pancreas detects that blood glucose is not falling as it should, and compensates by producing even more insulin. This state of chronically elevated insulin — hyperinsulinaemia — is at the heart of the problem.
Hyperinsulinaemia has several metabolically damaging consequences:
Over time, if the state persists, beta cells cannot keep pace with the demand for excess insulin production. Blood glucose begins to rise above normal fasting levels — first into the pre-diabetes range, and eventually into type 2 diabetes mellitus (T2DM) territory. Insulin resistance is not merely a precursor to T2DM; it is its foundational mechanism.
The scale of insulin resistance in Australia is significant and likely underestimated, because the condition is clinically invisible until late-stage markers appear.
According to the Australian Institute of Health and Welfare (AIHW):
These figures reflect what clinicians describe as a silent epidemic. Insulin resistance causes no acute symptoms in its early years, even as it progressively damages metabolic health, increases cardiovascular risk, and makes weight loss increasingly difficult.
Because insulin resistance develops gradually, many people have it for years before receiving a formal diagnosis. There are, however, observable signs and symptoms that warrant investigation:
Physical signs:
Metabolic and energy symptoms:
Blood marker patterns:
Associated conditions:
Insulin resistance is not routinely tested in standard GP blood panels — and that is a significant gap, because by the time HbA1c or fasting glucose are flagged as abnormal, insulin resistance has typically been present for a decade or more. The most practically useful test is fasting insulin, which is available through standard pathology in Australia and can be ordered by any GP.
Fasting serum insulin is measured after an overnight fast. Reference ranges vary between laboratories, but levels above 12–15 mIU/L are generally considered indicative of insulin resistance, even if fasting glucose remains normal.
The most clinically useful derived measure is HOMA-IR (Homeostatic Model Assessment of Insulin Resistance), calculated as:
HOMA-IR = (Fasting insulin [mIU/L] × Fasting glucose [mmol/L]) ÷ 22.5
Interpretation:
As an example: a fasting insulin of 14 mIU/L with a fasting glucose of 5.4 mmol/L gives a HOMA-IR of (14 × 5.4) ÷ 22.5 = 3.36 — clearly in the insulin-resistant range, despite glucose being technically within the normal fasting reference interval.
Any GP can order fasting insulin alongside a standard metabolic panel — it simply needs to be specifically requested, as it is not part of standard annual health checks. Functional medicine practitioners, endocrinologists, and integrative GPs are particularly familiar with HOMA-IR interpretation. Pathology labs across Australia (Sonic, Sullivan Nicolaides, Dorevitch) all perform fasting insulin assays. The cost under Medicare is minimal when bundled with other metabolic tests.
Diet is the most powerful lever for improving insulin sensitivity outside of pharmaceuticals — and the dietary changes required are sustainable, not extreme.
The core dietary principle for insulin resistance is not low-carbohydrate per se — it is carbohydrate quality. High-glycaemic-index (GI) carbohydrates — white bread, white rice, refined cereals, sugary drinks — produce rapid, large blood glucose spikes that demand high insulin output. Repeated throughout the day, every day, this chronically elevates insulin levels and worsens resistance.
Shifting to low-GI carbohydrate sources — legumes, intact whole grains, most vegetables, and most fruits — reduces the glycaemic burden on the pancreas without requiring carbohydrate elimination.
For people with more significant insulin resistance or pre-diabetes, a moderate carbohydrate reduction (targeting 100–130 g of carbohydrates per day, prioritising low-GI sources) consistently produces clinically meaningful improvements in fasting insulin, HOMA-IR, and HbA1c. Pairing this with a well-structured caloric deficit — including TDEE calculation and adequate protein targets — is the most reliable framework for achieving the 5–10% body weight reduction that independently reverses insulin resistance.
Higher protein intake improves insulin sensitivity through multiple mechanisms: it reduces appetite and caloric intake, preserves lean muscle mass during weight loss (critical because muscle is the primary site of glucose disposal), and has a minimal direct insulin-stimulating effect compared to carbohydrates. Our detailed protein and weight loss guide covers optimal protein targets and food sources.
Soluble fibre — found in oats, barley, legumes, psyllium, and many vegetables — blunts post-meal glucose spikes by slowing gastric emptying and reducing the rate of glucose absorption from the small intestine. Fermentable fibres are also fermented by gut bacteria into short-chain fatty acids (SCFAs), which directly improve insulin sensitivity in adipose tissue and the liver.
Aiming for 30–40 g of total dietary fibre per day, with emphasis on soluble and fermentable sources, is a meaningful and evidence-based dietary target. The gut microbiome and weight loss connection extends well beyond fibre delivery — specific bacterial species regulate GLP-1 and PYY secretion, bile acid metabolism, and systemic inflammation, meaning microbiome composition is itself a meaningful metabolic variable in insulin resistance.
Of all dietary patterns studied in randomised controlled trials, the Mediterranean diet has the most consistent evidence base for improving insulin sensitivity. A 2020 meta-analysis of 29 trials found Mediterranean diet adherence was associated with significantly reduced HOMA-IR, fasting insulin, fasting glucose, and HbA1c. The diet's combination of olive oil (polyphenols, monounsaturated fats), fish (omega-3 fatty acids), legumes (protein and soluble fibre), vegetables, and moderate whole grains addresses insulin resistance through multiple simultaneous mechanisms.
If diet is the strongest dietary lever, exercise is the strongest overall non-pharmacological intervention for insulin resistance — and the mechanisms are distinct from diet, meaning the two are additive.
Skeletal muscle is the body's largest glucose disposal organ — responsible for roughly 80% of glucose uptake following a meal under insulin-stimulated conditions. Resistance training improves insulin sensitivity through a mechanism that operates independently of insulin itself: the translocation of GLUT4 glucose transporters to the muscle cell surface.
During and immediately after each set of resistance exercise, muscle contractions trigger GLUT4 transporters to move to the cell membrane, enabling glucose uptake without requiring insulin signalling. This effect persists for 24–48 hours post-exercise. Regular resistance training also increases total GLUT4 protein expression in muscle tissue — meaning the effect becomes chronic, not just acute.
Practically, two to three resistance training sessions per week produce measurable and sustained reductions in HOMA-IR. Even bodyweight-only training — squats, lunges, push-ups — is sufficient to engage this mechanism. High-intensity interval training also drives rapid GLUT4 upregulation and is particularly time-efficient for improving insulin sensitivity — HIIT protocols and the research behind them are examined in detail separately.
Zone 2 aerobic exercise — sustained moderate-intensity effort at roughly 60–70% of maximum heart rate — is the most effective exercise intensity for improving mitochondrial density in skeletal muscle and the liver. More mitochondria mean greater capacity to oxidise fatty acids and glucose, improving both metabolic flexibility and insulin sensitivity.
Thirty to forty minutes of zone 2 cardio four times per week produces significant mitochondrial adaptations within 8–12 weeks. Activities that achieve this intensity include brisk walking, cycling, swimming, and rowing.
One of the most practical and evidence-backed interventions for insulin resistance is also among the simplest: a 10-minute walk after meals. Multiple studies show that a post-meal walk reduces the post-prandial glucose spike by approximately 30% compared to remaining seated. This is clinically meaningful — repeated three times daily, it substantially reduces the total glycaemic load the pancreas must manage. For people who cannot commit to structured exercise sessions, starting with post-meal walking is an excellent and effective entry point.
Consider pairing this with intermittent fasting, which compounds the insulin-sensitising effect by extending the low-insulin periods between meals.
No supplement should be considered a substitute for dietary and exercise intervention, but several have genuine, mechanistically supported evidence for improving insulin sensitivity as an adjunct to lifestyle measures.
Berberine is a plant alkaloid extracted from plants including barberry and goldenseal. It activates AMPK (adenosine monophosphate-activated protein kinase) — the same cellular energy sensor activated by exercise and metformin — which improves glucose uptake in muscle and reduces hepatic glucose production.
Multiple randomised controlled trials have compared berberine to metformin in individuals with type 2 diabetes, finding comparable reductions in fasting glucose, post-meal glucose, and HbA1c. A 2012 meta-analysis in the Journal of Ethnopharmacology (14 RCTs, 1,068 patients) confirmed berberine's glucose-lowering efficacy. For insulin resistance specifically, berberine studies show reductions in fasting insulin and HOMA-IR. Typical dosing in trials: 500 mg two to three times daily with meals.
Magnesium deficiency is common in Westernised populations and is independently associated with worsened insulin resistance. Magnesium is required for over 300 enzymatic reactions, including those involved in insulin receptor signalling and glucose metabolism.
A 2016 meta-analysis of 25 RCTs found magnesium supplementation significantly improved fasting glucose and insulin sensitivity in individuals who were magnesium deficient or insulin resistant. Magnesium glycinate or magnesium malate are generally better tolerated than magnesium oxide.
Chromium potentiates the action of insulin at the receptor level. Evidence from RCTs is mixed and generally shows modest effects — reductions in fasting glucose of approximately 0.5–1.0 mmol/L in studies of chromium picolinate. The effect is most relevant in individuals with documented chromium insufficiency.
Myo-inositol and D-chiro-inositol are insulin second messengers that mediate glucose uptake at the cellular level. Inositol is particularly relevant in the PCOS context, where insulin resistance is common and inositol signalling is frequently impaired. Multiple trials show myo-inositol supplementation significantly reduces fasting insulin, HOMA-IR, and testosterone in PCOS. Evidence in insulin resistance without PCOS is more limited but mechanistically plausible.
EPA and DHA (marine omega-3s) reduce hepatic fat accumulation — one of the primary drivers of hepatic insulin resistance. Multiple trials show fish oil supplementation reduces liver fat content measured by MRI or ultrasound, alongside improvements in insulin sensitivity markers. The evidence for improving HOMA-IR is moderate but consistent. Dosing in trials is typically 2–4 g EPA+DHA daily.
For individuals with significant insulin resistance, pre-diabetes, or established T2DM, lifestyle measures may be insufficient on their own. Several evidence-based medications work through complementary mechanisms.
Metformin remains the first-line pharmacological treatment for type 2 diabetes and is also widely used off-label in pre-diabetes and insulin resistance. Its primary mechanism is reduction of hepatic glucose output — inhibiting gluconeogenesis (the liver's production of new glucose). It also activates AMPK, similarly to berberine and exercise, improving peripheral insulin sensitivity.
Metformin is inexpensive, well-tolerated, has a 60-year safety record, and has evidence for modest cardiovascular benefit beyond glucose control. In the landmark UK Prospective Diabetes Study (UKPDS), metformin reduced cardiovascular events in overweight T2DM patients by 39% over diet alone. It is available on the PBS in Australia for T2DM.
GLP-1 agonists — including semaglutide (Ozempic, Wegovy) and liraglutide — address insulin resistance through multiple simultaneous pathways: reducing visceral fat (which is itself a driver of insulin resistance), improving beta cell function, reducing hepatic fat accumulation, and lowering the glycaemic load through appetite suppression and delayed gastric emptying.
In the SUSTAIN and STEP trial programmes, semaglutide produced weight loss of 10–15% of body weight alongside substantial improvements in HbA1c, fasting insulin, and cardiovascular markers. See our comprehensive guide to Ozempic in Australia for current access and cost information.
For those following the broader landscape of peptide-based metabolic science, insulin sensitising peptide research is an active and evolving area of interest.
Sodium-glucose cotransporter 2 inhibitors — including empagliflozin, dapagliflozin, and canagliflozin — reduce blood glucose by causing the kidneys to excrete excess glucose in the urine, independent of insulin. This insulin-independent glucose disposal reduces the demand on the pancreas, improves beta cell function over time, and promotes modest weight loss and visceral fat reduction.
SGLT2 inhibitors have also demonstrated significant cardiovascular and renal protective benefits in large outcome trials, and are now considered standard of care in T2DM patients with established cardiovascular disease or chronic kidney disease.
Tirzepatide (Mounjaro) is the newest class of metabolic medication — a dual agonist of both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. In the SURMOUNT-1 trial, tirzepatide produced weight loss of up to 22.5% of body weight — greater than any prior medication. Alongside this, insulin resistance reversal is profound: HbA1c reductions averaging 2.0–2.1 percentage points and near-normalisation of fasting insulin in pre-diabetic participants.
You can also explore natural ways to support GLP-1 for adjunctive lifestyle approaches alongside these medications.
Diet and exercise receive most of the attention in insulin resistance management — but the roles of sleep and stress are mechanistically important and clinically underappreciated.
A single night of insufficient sleep — less than 6 hours — has been shown in controlled sleep restriction studies to produce a 25% reduction in insulin sensitivity the following day, measurable by HOMA-IR and euglycaemic clamp. This is a dramatic acute effect, and chronic sleep restriction produces chronic insulin sensitivity impairment.
The mechanisms include elevated cortisol and growth hormone during sleep deprivation (promoting hepatic glucose production), increased ghrelin and reduced leptin (driving appetite and carbohydrate craving), and sympathetic nervous system activation (which impairs peripheral glucose uptake).
For individuals managing insulin resistance, prioritising 7–9 hours of quality sleep is not a lifestyle luxury — it is a metabolic intervention. The full hormonal science behind how poor sleep drives fat gain and disrupts appetite hormones — including the specific effects on ghrelin, leptin, GLP-1, and cortisol — is examined in detail in the sleep and weight loss guide.
Sleep apnoea — which disproportionately affects people with central obesity and insulin resistance — worsens insulin sensitivity through chronic nocturnal hypoxia and cortisol elevation. Treating sleep apnoea with CPAP is associated with meaningful improvements in insulin sensitivity independent of weight change.
Cortisol is the body's primary stress hormone, released by the adrenal glands in response to psychological and physiological stress. Cortisol drives hepatic glucose production (gluconeogenesis) — a survival mechanism to ensure glucose availability during perceived threats. In states of chronic stress, this translates to persistently elevated blood glucose that demands elevated insulin output. The full mechanism by which chronic stress and cortisol drive fat storage and insulin resistance — including visceral adiposity and appetite disruption — is covered in a dedicated guide.
Cortisol also promotes central fat deposition (Cushing's syndrome is the extreme example — cortisol excess produces exactly the visceral adiposity pattern of insulin resistance), directly impairs insulin receptor signalling in peripheral tissues, and elevates free fatty acids in the circulation, which worsen hepatic insulin resistance.
Stress management interventions — including mindfulness-based stress reduction (MBSR), yoga, and diaphragmatic breathing — have demonstrated small but consistent reductions in cortisol and associated improvements in fasting glucose and insulin in clinical trials. These are genuine metabolic interventions, not merely wellness adjuncts.
One of the most common questions people with insulin resistance ask is how long reversal takes. The first improvements come quickly, but meaningful metabolic normalisation takes months.
Week 1: A single session of resistance training improves insulin sensitivity for 24–48 hours. Starting post-meal walking immediately produces measurable reductions in post-prandial glucose. These early effects are real and motivating, even though they do not yet reflect structural metabolic change.
Weeks 2–4: Dietary quality improvements begin to reduce average fasting insulin levels. Triglycerides — which are highly sensitive to carbohydrate intake — often fall noticeably within 2–4 weeks of reducing refined carbohydrates.
Weeks 4–8: Regular exercise (2–3 resistance training sessions plus zone 2 cardio per week) produces measurable GLUT4 upregulation in muscle tissue. HOMA-IR typically shows clinically meaningful improvement in this window in people adhering to both diet and exercise changes.
3–6 months: Clinically significant reductions in HOMA-IR, fasting insulin, and HbA1c are typically measurable by this point with consistent adherence. A 5–10% reduction in body weight — achievable in this timeframe — independently improves insulin sensitivity substantially, as visceral fat (the primary driver of systemic insulin resistance) is preferentially mobilised during weight loss.
Full reversal from pre-diabetes: The landmark US Diabetes Prevention Program (DPP) trial showed that intensive lifestyle intervention (7% weight loss plus 150 minutes of moderate exercise per week) reduced progression from pre-diabetes to T2DM by 58% over 3 years. In those who achieved full reversal of pre-diabetes, the benefit was durable long-term. The majority of people with pre-diabetes who implement meaningful lifestyle change can achieve normal glucose regulation. Full reversal of established T2DM is harder but documented in studies of significant weight loss, most notably the DiRECT trial (50% of participants achieved remission at 12 months with a structured low-calorie diet programme).
Yes — in most cases, insulin resistance is reversible, particularly in the early and moderate stages. Pre-diabetes driven by insulin resistance can be fully reversed through lifestyle change in a significant proportion of people. Even established type 2 diabetes can be put into remission — normal HbA1c without medication — through sufficient weight loss and dietary change, as demonstrated in the DiRECT trial. The earlier insulin resistance is identified and addressed, the more complete the reversal.
Initial improvements in insulin sensitivity appear within days of starting exercise and within 2–4 weeks of meaningful dietary change. Clinically measurable reversal, reflected in improved HOMA-IR and fasting insulin, typically takes 4–12 weeks of consistent lifestyle change. Full reversal of pre-diabetes to normal metabolic markers generally takes 3–12 months depending on baseline severity, the degree of weight loss achieved, and consistency of adherence.
There is no single universally optimal diet, but the consistent evidence-based principles are: prioritise carbohydrate quality over quantity (low-GI, high-fibre carbohydrates); increase protein intake to preserve muscle and reduce appetite; minimise ultra-processed foods, refined carbohydrates, and liquid calories; and include anti-inflammatory fats from olive oil, fish, nuts, and avocado. The Mediterranean dietary pattern has the strongest overall evidence base. For people with significant insulin resistance or pre-diabetes, moderate carbohydrate reduction (targeting 100–130 g/day of primarily low-GI carbohydrates) typically produces faster initial improvements in HOMA-IR.
No. Metformin is the most commonly used first-line agent and has the longest evidence record, but the pharmaceutical options have expanded substantially. GLP-1 receptor agonists (semaglutide, liraglutide) produce significant insulin sensitivity improvement alongside meaningful weight loss. SGLT2 inhibitors (empagliflozin, dapagliflozin) improve glucose management through insulin-independent mechanisms with additional cardiovascular and renal benefits. Tirzepatide, the dual GLP-1/GIP agonist, produces the largest weight loss and insulin resistance reversal of any currently available medication. The right approach depends on individual clinical context and should be discussed with a GP or endocrinologist.
Yes — intermittent fasting is one of the more effective dietary approaches for insulin resistance. Extended periods without eating allow insulin levels to fall to their baseline, reducing the chronically elevated insulin exposure that drives resistance. Time-restricted eating (e.g., 16:8 or 14:10 windows) also concentrates caloric intake earlier in the day when insulin sensitivity is naturally higher. Multiple RCTs show intermittent fasting reduces fasting insulin and HOMA-IR comparably or better than continuous caloric restriction of equivalent energy deficit. It is a valuable tool for those who find it sustainable, but not mandatory — consistent dietary quality improvement works regardless of meal timing.
HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is a calculated measure of insulin resistance derived from fasting insulin and fasting glucose: (fasting insulin × fasting glucose) ÷ 22.5. Values below 1.5 reflect optimal insulin sensitivity; values above 2.5 indicate significant insulin resistance. To get it tested in Australia, ask your GP to add fasting insulin to a standard metabolic blood panel — fasting glucose is usually already included. Any GP can order this at any major Australian pathology provider. You calculate HOMA-IR yourself from the two results, or ask your GP or a functional medicine practitioner to assist with interpretation.
Eli Lilly's orforglipron is the first non-peptide oral GLP-1 agonist with full Phase 3 data. This guide covers the ATTAIN-1 obesity trial, the ACHIEVE-1 T2D trial, weight loss versus injectable semaglutide and tirzepatide, side-effect profile, and Australian timeline implications.
A detailed breakdown of the TRIUMPH-1 Phase 3 trial results for retatrutide — the triple-hormone agonist that achieved up to 28.3% mean weight loss at 80 weeks and ~30.3% in a higher-BMI subgroup at 104 weeks.
Is body recomposition possible? The evidence says yes — under specific conditions. Here's the science behind losing fat and gaining muscle at the same time, including protein targets, training requirements, and realistic timelines.